[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-system-atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-system-atrophy":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,50,77,101,124,152,184,204,237,259,284,309,329,350,363,388,423,448,473,495,517,542,567,587,606],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100422592","use-of-accelerometer-for-quantification-of-neurogenic-orthostatic-hypotension-symptoms-100422592",false,"NCT04782830","Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms","Inclusion Criteria:\n\n* Male and female subjects, age 40-80 years.\n* Possible or probable Multiple Systems Atrophy, Pure Autonomic Failure, or Parkinson's disease with neurogenic orthostatic hypotension.\n* Neurogenic orthostatic hypotension defined as a ≥ 30 mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes.\n* Patients on treatment for neurogenic orthostatic hypotension with either midodrine or atomoxetine, who have experienced some improvement in their orthostatic symptoms, but still remain symptomatic (Orthostatic hypotension symptom assessment \\[OHSA\\] score of 1 to 5 while on medication).\n* Patients who are able to stay with their caregiver during study participation.\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Bedridden, physically disabled, or unable to walk.\n* Patients with Orthostatic hypotension symptom assessment (OHSA) score ≥ 6, or orthostatic systolic blood pressure drop ≥ 30 mmHg on their regular treatment.\n* Patients taking more than one medication for the treatment of neurogenic orthostatic hypotension (concomitant use of pyridostigmine or fludrocortisone are accepted).\n* Pregnancy\n* Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies.\n* Clinically unstable coronary artery disease (recurrent angina despite medical therapy), or major cardiovascular or neurological event in the past 6 months (myocardial infarction, stroke).\n* Concomitant use of anticoagulants.","ALL","40 Years","80 Years",{"count":20,"type":21},29,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to find a more objective and accurate way to assess the efficacy of the treatment for neurogenic orthostatic hypotension. For this purpose, the investigators will use an activity monitor to determine the amount of time patients spend in the upright position (standing and walking; upright time) during 1 week of placebo (a pill with no active ingredients) and 1 week of their regular medication for orthostatic hypotension (midodrine or atomoxetine at their usual doses). Total upright time (i.e. tolerance to standing and walking) will be compared between placebo and active treatment to test the hypothesis that it can be used to assess the efficacy of the treatment for orthostatic hypotension and whether this outcome is superior to the assessment of symptoms using validated questionnaires.",[27,28,29,30,31],"Orthostatic; Hypotension, Neurogenic","Autonomic Failure","Pure Autonomic Failure","Multiple System Atrophy","Orthostatic; Hypotension, Parkinsonism",[33,34,35,36],"orthostatic hypotension","autonomic failure","accelerometer","orthostatic symptoms","RECRUITING","2026-06-29",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":41},"2021-02-05",{"date":45,"type":21},"2027-10-01",{"name":47,"class":48},"Vanderbilt University Medical Center","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100636786","individualized-transcranial-magnetic-stimulation-in-parkinsonian-disorders-100636786","NCT07570212","Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders","Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders","Inclusion Criteria:\n\n1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.\n2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.\n3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.\n4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic\u002Fmagnetic fragments.\n2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.\n3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).\n4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.\n5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.","30 Years",{"count":59,"type":21},50,[24],"This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders. The main question it aims to answer is:\n\n* Does individualized targeted rTMS alleviate symptoms of parkinsonian disorders?\n* Which clinical manifestations of parkinsonian syndromes are responsive to individualized targeted rTMS, and to what degree?\n\nProcedures:\n\n* Preparation (Screening) Participants will undergo clinical assessments, MRI, and EEG before the treatment.\n* Treatment (2 Weeks) Participants will receive a 10-day TMS treatment (once daily, Monday-Friday). Each treatment day takes approximately 3-4 hours. Participants need to keep stable medications and rehabilitation routines during this time.\n* Follow-up (10 Weeks) Participants will undergo follow-up assessments at the end of treatment and 10 weeks after treatment. Assessments include clinical scales, MRI, and EEG.",[63,30,64],"Parkinson's Disease","Progressive Supranuclear Palsy",[66,67,68],"parkinsonian disorders","transcranial magnetic stimulation","somato-cognitive action network","2026-06-24",{"date":38,"type":41},{"date":72,"type":41},"2025-12-22",{"date":74,"type":21},"2027-12-22",{"name":76,"class":48},"Peking University First Hospital",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100608154","phase-2-an-extension-trial-to-test-if-tev-56286-is-effective-in-relieving-multiple-system-atrophy-100608154","NCT07197866","An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy","An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy","Inclusion Criteria:\n\n* Completion of the treatment period and the week 48(V9) visit of the double-blind trial (TV56286-NDG-20039) whilst remaining compliant with trial requirements\n* Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit\n* Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the trial and for 28 days after the last does of IMP\n* Males who are potentially fertile\u002Freproductively competent (not surgically \\[eg, vasectomy\\] or congenitally sterile) and their female partners who are of childbearing potential must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 28 days after the last dose of investigational medicinal product\n\nNOTE - Additional criteria apply, please contact the investigator for more information\n\nExclusion Criteria:\n\n* Is a female participant who is pregnant, plans to become pregnant, or is breastfeeding during the trial\n* Is of a vulnerable population (eg, people kept in detention or jail)\n* Is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this trial\n\nNote - Additional criteria apply, please contact the investigator for more information",{"count":85,"type":21},200,[87],"PHASE2","The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).\n\nA secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.\n\nThe planned total duration of the trial is approximately 100 weeks.",[30],"2026-06-16",{"date":92,"type":41},"2026-06-17",{"date":94,"type":41},"2025-09-30",{"date":96,"type":21},"2029-05-17",{"name":98,"class":99},"Teva Branded Pharmaceutical Products R&D LLC","INDUSTRY",27,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100559753","phase-2-a-trial-to-test-if-tev-56286-is-effective-for-treatment-of-participants-with-multiple-system-atrophy-100559753","NCT06568237","A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy","A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)","TOPAS-MSA","Inclusion Criteria:\n\n* is considered to be \"clinically possible\" or \"clinically probable\" MSA as determined by the Gilman criteria\n* is medically and psychiatrically stable, as indicated by medical and psychiatric history, as well as physical and neurological examination\n* Females of child bearing potential (CBP) may be included only if they have a negative pregnancy test at the screening and baseline visits\n* Females of CBP whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods\n* Males who are potentially fertile\u002Freproductively competent (not surgically \\[eg, vasectomy\\] or congenitally sterile) and their female partners who are of CBP must use, together with their female partners, highly effective birth control methods\n\n  * Additional criteria apply; please contact the investigator for more information\n\nExclusion Criteria:\n\n* has 2 or more relatives with history of MSA, suggestive of an alternative diagnosis other than MSA\n* has participated in another clinical study involving administration of an IMP within 3 months or 5 half-lives (whichever is longer) of this IMP prior to screening\n* has a history of, or acknowledges, alcohol or other substance abuse in the 12 months before screening\n* is a female participant who is pregnant or breastfeeding, or plans to become pregnant during the study\n* has a known hypersensitivity to any components of the IMP\n* is of a vulnerable population (eg, people kept in detention or jail)\n* participant is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this study\n\n  * Additional criteria apply; please contact the investigator for more information","75 Years",{"count":111,"type":21},350,[87],"The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).\n\nA secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286.\n\nAnother secondary objective is to evaluate the safety and tolerability of TEV-56286.\n\nThe planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.",[30],[116],"Multiple System Atrophy (MSA)",{"date":92,"type":41},{"date":119,"type":41},"2024-10-02",{"date":121,"type":21},"2027-09-15",{"name":98,"class":99},60,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":16,"minAge":130,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100193894","natural-history-study-of-synucleinopathies-100193894","NCT01799915","Natural History Study of Synucleinopathies","Inclusion Criteria:\n\n1. Both male and female patients will be included\n2. Aged 18 or over\n3. Referred to any of the participating consortium sites with orthostatic intolerance, defined as symptoms of dizziness or lightheadedness in the standing position that disappear when supine.\n\nExclusion Criteria:\n\n1. Diabetes according to the American Diabetes Association criteria\n2. Congestive heart failure\n3. Lupus or other collagen vascular disease\n4. Systemic illness thought to be responsible for the orthostatic intolerance\n5. Drug-induced orthostatic hypotension (i.e., the use of alpha-blockers, diuretics, tricyclic antidepressants or others thought by the investigator to play an important role in the patient's orthostatic hypotension)\n6. Isolated vasovagal syncope\n7. Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.","18 Years",{"count":132,"type":21},800,"OBSERVATIONAL","Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control of movement or cognition. Patients with synucleinopathies and signs of CNS-deficits are frequently diagnosed with Parkinson disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA).\n\nHowever, accumulation of alpha-synuclein and death of nerve cells can also begin outside the brain in the autonomic nerves. In such cases, syncucleinopathies present first with symptoms of autonomic impairment (unexplained constipation, urinary difficulties, and sexual dysfunction). In rare cases, hypotension on standing (a disorder known as orthostatic hypotension) may be the only clinical finding. This \"pre-motor\" autonomic stage suggests that the disease process may not yet have spread to the brain.\n\nAfter a variable period of time, but usually within 5-years, most patients with abnormally low blood pressure on standing develop cognitive or motor abnormalities. This stepwise evolution indicates that the disease spreads from the body to the brain. Another indication of this spread is that acting out dreams (i.e., REM sleep behavior disorder, RBD) a problem that occurs when the lower part of the brain is affected, may also be the first noticeable sign of Parkinson disease.\n\nThe purpose of this study is to document the clinical features and biological markers of patients with synucleinopathies and better understand how these disorders evolve over time. The study will involve following patients diagnosed with a synucleinopathy (PD\u002FDLB and MSA) and those believed to be in the \"pre-motor\" stage (with isolated autonomic impairment and\u002For RBD). Through a careful series of follow-up visits to participating Centers, we will focus on finding biological clues that predict which patients will develop motor\u002Fcognitive problems and which ones have the resilience to keep the disease at bay preventing spread to the brain. We will also define the natural history of MSA - the most aggressive of the synucleinopathies.",[136,137,29,138,139,140,30,141],"Patients With Synucleinopathies","Neurogenic Orthostatic Hypotension","REM Sleep Behavior Disorder","Parkinson Disease","Dementia With Lewy Bodies","Shy-Drager Disease","2026-06-09",{"date":144,"type":41},"2026-06-10",{"date":146,"type":41},"2011-06",{"date":148,"type":21},"2026-12-30",{"name":150,"class":48},"NYU Langone Health",8,{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":161,"targetDuration":163,"studyType":133,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":49},"100642000","prospective-multicenter-registry-study-of-multiple-system-atrophy-in-china-100642000","NCT07644013","Prospective Multicenter Registry Study of Multiple System Atrophy in China","Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China","MSA Registry S","Inclusion Criteria\n\n1. Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or\n2. Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or\n3. Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.\n4. Age between 40 and 75 years.\n5. Ability to provide informed consent or availability of a legally authorized representative when applicable.\n\nExclusion Criteria\n\n1. Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.\n2. Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.\n3. Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.\n4. Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.\n5. Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.\n6. Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.",true,{"count":162,"type":21},214,"6 Months","Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited.\n\nThis prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.",[30,63,166],"Atypical Parkinsonism",[168,169,170,171,172,173,174,175],"Multiple system atrophy","natural history","prospective cohort","multicenter registry","disease progression","neuroimaging","biomarkers","alpha-synuclein","2026-06-08",{"date":178,"type":41},"2026-06-12",{"date":180,"type":41},"2025-06-01",{"date":182,"type":21},"2030-06-30",{"name":76,"class":48},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":49},"100582847","phase-2-a-phase-2a-study-of-foralumab-nasal-in-patients-with-multiple-system-atrophy-msa-100582847","NCT06868628","A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)","A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)","Inclusion Criteria:\n\n* Subjects with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic criteria.\n* Age 30 to 85 years, at the time of signing the informed consent.\n* Stable dopaminergic treatment for at least 4 weeks before enrollment.\n* Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g\u002FdL; Platelets ≥ 100 x 109 cells\u002FL.\n* Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL\u002Fminute x 1.73 m2 per the Cockcroft-Gault formula.\n* Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease.\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN.\n* QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening.\n* Negative urine pregnancy test within 7 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male patients must agree to use highly effective methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 90 days after the completion of study treatment.\n* Patients whose immunizations are fully up to date at the Screening, according to the assessment of their primary care physician and neurologist.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis.\n* Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study.\n* Individuals with claustrophobia who cannot tolerate the study procedures\n* Non-MRI-compatible implanted devices.\n* Low-affinity binders for translocator protein (TSPO) PET ligands.\n* Systemic corticosteroid treatment in the past four weeks (excluding nasal or local treatment).\n* Individuals with significant cognitive impairment (i.e., MoCA score less than or equal to 20).\n* Brain MRI indicative of significant abnormalities that interfere with PET-MRI co-registration (i.e., large prior hemorrhage or multiple infarcts).\n* Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV or hereditary long QT syndrome.\n* Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care.\n* Patients who test positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or positive Epstein-Barr virus (EBV) IgM at the Screening Visit.\n* Past medical history of a hematologic or solid malignancy.\n* Treatment with chronic immunosuppressives such as interferon, glatiramer acetate, fingolimod, Siponimod, dimethyl fumarate, or natalizumab within the past 90 days.\n* Inability to tolerate nasally administered medications.\n* Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days, or anticipated need during the study.\n* Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 8 months.\n* Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's Syndrome, asthma, or type 1 diabetes.\n* Neutropenia or an absolute neutrophil count of \\\u003C 1,000 cells\u002FmL or other indicators of severe immunosuppression.\n* Severe lymphopenia or an absolute lymphocyte count of \\\u003C 500 cells\u002FmL\n* Patients with a history of gadolinium allergy.\n* A recent clinically significant active infection requiring treatment with antibiotics or other anti-infective agents within the past 15 days.\n* Any other medical or surgical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results.\n* Unable or unwilling to comply with protocol requirements.\n* Active COVID-19 disease.\n* COVID-19 vaccine within past 10 days or any other vaccine within past 7 days (at dosing).","85 Years",{"count":193,"type":21},5,[87],"A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)",[30],{"date":144,"type":41},{"date":199,"type":41},"2025-05-19",{"date":201,"type":21},"2027-04-01",{"name":203,"class":99},"Tiziana Life Sciences LTD",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":160,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":212,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":236},"100640300","early-molecular-biomarkers-for-differentiating-parkinsonian-syndromes-100640300","NCT07604883","Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes","Identification of Molecular Biomarkers, Including microRNAs and Metabolites, Enabling Early Differentiation of Parkinson's Disease and Atypical Parkinsonian Syndromes in a Prospective Observational Study.","BIOMARK-PS","Inclusion Criteria:\n\nPatients with suspected neurodegenerative parkinsonism in the course of PD or APS, defined according to the 2015 MDS criteria as bradykinesia accompanied by at least one additional symptom: rigidity and\u002For resting tremor.\n\nAge between 40 and 80 years. Written informed consent for participation in the study. Duration of parkinsonian symptoms shorter than 3 years. Abnormal dopamine transporter single-photon emission computed tomography (DaTscan) result confirming presynaptic dopaminergic neuronal degeneration.\n\nExclusion Criteria Lack of consent to participate in the study. Secondary or drug-induced parkinsonism. Other central nervous system (CNS) disorders (e.g., neoplastic or vascular processes) that could account for the symptoms.\n\nActive malignancy, infection, or autoimmune inflammatory disease. Severe systemic diseases, including advanced heart failure (New York Heart Association \\[NYHA\\] class III-IV), poorly controlled diabetes mellitus, renal failure with glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin\u002F1.73 m², or hepatic failure.\n\nPresence of a known monogenic mutation causing parkinsonism according to the Online Mendelian Inheritance in Man (OMIM) classification.\n\nAntibiotic therapy or use of probiotics within 3 months prior to the study visit.\n\nPregnancy or breastfeeding.",{"count":85,"type":21},"This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian syndromes (APS). The study will enroll up to 100 patients with PD, 50 patients with suspected APS, and 50 healthy controls.\n\nParticipants will undergo clinical assessments and provide blood, urine, and stool samples at baseline and after 12-18 months of follow-up. Molecular analyses, including microRNA profiling, metabolomics, RNA sequencing (RNA-seq), and microbiome analysis, will be performed to identify disease-specific diagnostic signatures.\n\nThe primary objective is to detect differences in molecular profiles among patients with PD, patients with APS, and healthy controls. Secondary objectives include evaluating the diagnostic accuracy of biomarker panels and assessing longitudinal changes in these biomarkers over time.\n\nAlthough participants will not receive direct therapeutic benefits, the study may contribute to the development of non-invasive tools for the early diagnosis and improved differentiation of parkinsonian disorders.",[215,166,30,216,217],"PARKINSON DISEASE (Disorder)","Progressive Supranuclear Palsy (PSP)","Dementia With Lewy Bodies (DLB)",[219,220,221,222,223,224],"parkinson disease","atypical parkinsonism","progressive supranuclear palsy","multiple system atrophy","dementia with lewy bodies","biomarker","NOT_YET_RECRUITING","2026-05-25",{"date":228,"type":41},"2026-05-28",{"date":230,"type":21},"2026-06-04",{"date":232,"type":21},"2029-06-04",{"name":234,"class":235},"International Institute of Molecular and Cell Biology in Warsaw","OTHER_GOV",2,{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100581278","phase-2-a-phase-2-study-of-ya-101-in-patients-with-multiple-system-atrophy-100581278","NCT06848231","A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy","A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy","Inclusion Criteria:\n\n1. Able to understand the process of the clinical trial and give informed consent for the participation of the study.\n2. Diagnosis of MSA according to MDS clinical criteria (Wenning et al, 2022), including subjects with MSA of either subtype (MSA-P or MSA-C).\n3. Males or non-pregnant, non-lactating females with no child-bearing potential, or agree to use 2 forms of contraception.\n4. Able to take oral medications.\n5. Able to ambulate without the assistance of another person.\n\nExclusion Criteria:\n\n1. Positive urine test for drugs of abuse and\u002For alcohol test both at screening and Day 1.\n2. Evidence of renal impairment or hepatic impairment.\n3. Subject with a Mini-Mental State Examination (MMSE) score of 24 or lower.\n4. Medical history includes severe systemic diseases such as cardiopulmonary failure, severe liver or kidney disease, and uncontrolled diabetes; significant central nervous system disorders like stroke, encephalitis, and epilepsy and severe head trauma; peptic ulcer in one year prior to screening.\n5. Positive results for active viral infections, including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.",{"count":245,"type":21},75,[87],"This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.",[30],"2026-04-28",{"date":251,"type":41},"2026-04-29",{"date":253,"type":41},"2025-03-03",{"date":255,"type":21},"2026-12-31",{"name":257,"class":99},"Dasher Neuroscience Inc.",9,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100375208","phase-1-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-ion464-administered-to-adults-with-multiple-system-atrophy-horizon-100375208","NCT04165486","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)","A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy","HORIZON","Key Inclusion Criteria:\n\n* Screening single-photon emission computed tomography (SPECT) with DaTscan™ (ioflupane I123 injection) results demonstrating loss (whether symmetric or asymmetric) of dopamine nerve terminals in the striatum consistent with neurodegenerative parkinsonism, as assessed with qualitative, visual read.\n* Diagnosed with probable or possible MSA, either parkinsonian-type (MSA-P) or cerebellar-type (MSA-C).\n* Must be able to walk unassisted for at least 10 meters (approximately 30 feet)\n\nKey Exclusion Criteria:\n\n* Presence of cognitive dysfunction (defined as Montreal Cognitive Assessment (MoCA) score \\\u003C25)\n* Family history of ataxia or parkinsonism and known genetic cause of ataxia or parkinsonism.\n\nNOTE: Other protocol defined Inclusion\u002F Exclusion criteria may apply.","70 Years",{"count":269,"type":21},40,[271],"PHASE1","The primary objectives are to evaluate the safety and tolerability of multiple doses of ION464 administered via intrathecal (IT) injection (Part 1) and to evaluate the long-term safety and tolerability of ION464 (Part 2) in participants with multiple system atrophy (MSA).\n\nThe secondary objectives are to evaluate the pharmacodynamic (PD) effect of ION464 on the level of a potential biomarker of target engagement (Parts 1 and 2) and to evaluate the pharmacokinetic (PK) profile of ION464 in serum (Part 1).",[30],"2026-04-24",{"date":276,"type":41},"2026-04-27",{"date":278,"type":41},"2022-07-21",{"date":280,"type":21},"2027-09",{"name":282,"class":99},"Ionis Pharmaceuticals, Inc.",15,{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":16,"minAge":291,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":49},"100422550","comprehensive-swallowing-rehabilitation-in-patients-with-msa-100422550","NCT04782284","Comprehensive Swallowing Rehabilitation in Patients With MSA","Effect of Comprehensive Swallowing Rehabilitation in Patients With Multiple System Atrophy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>19 years\n* Clinically diagnosed with MSA according to the guidelines of the 2nd consensus of the Gilman criteria\n* Clinically diagnosed to have dysphagia by a physiatrist\n* Two or more points on the Penetration-aspiration scale (PAS) from the Videofluoroscopic swallowing study (VFSS) conducted within 3 months\n\nExclusion Criteria:\n\n* Moderate to severe cognitive dysfunction with Mini-mental State Examination score \\\u003C 19\n* Comorbidities or structural abnormalities that may affect swallowing function\n* Other comorbidities that make it difficult to participate in the study","19 Years",{"count":293,"type":21},24,[24],"The purpose of this study is to investigate the effect of comprehensive swallowing rehabilitation in patients with multiple system atrophy.",[30],[30,298,299,300],"Dysphagia","Swallowing rehabilitation","Videofluoroscopic Swallowing Study","2026-04-22",{"date":276,"type":41},{"date":304,"type":41},"2021-05-17",{"date":306,"type":21},"2027-12-31",{"name":308,"class":48},"Seoul National University Hospital",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":16,"minAge":130,"maxAge":191,"enrollmentInfo":4,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":327,"locationsCount":49},"100611244","an-intermediate-size-patient-population-expanded-access-protocol-to-evaluate-the-safety-and-efficacy-of-allogeneic-hb-admscs-hope-biosciences---adipose-derived-mesenchymal-stem-cells-for-the-treatment-of-multiple-system-atrophy-100611244","NCT07238062","\"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy.\"","\"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Multiple System Atrophy.\"","Inclusion Criteria:\n\n1. Male and female participants 18-85 years of age\n2. Participants must have a diagnosis of \"Clinically Established\" or \"Clinically Probable\" MSA.\n3. Participants must have at least one brain MRI marker suggestive of MSA.\n4. Participants must have both autonomic failure and either poorly L-dopa-responsive parkinsonism or cerebellar ataxia.\n5. Female participants of childbearing potential should not be pregnant or plan to become pregnant during protocol participation and for 6 months after the last investigational product administration. Female participants of childbearing potential should confirm the use of one of the following contraceptive measures:\n\n   * Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal).\n   * Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).\n   * Barrier contraceptive methods (condoms, diaphragm, etc.).\n   * Surgery (occlusion bilateral tubal ligation, hysterectomy, vasectomized partner).\n\n   OR\n   * Male participants if their sexual partners can become pregnant should ensure the use one of the following methods of contraception during protocol participation and for 6 months after the last administration of the investigated product:\n   * Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal).\n   * Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).\n   * Barrier contraceptive methods (condoms, diaphragm, etc.).\n   * Surgery (vasectomy, occlusion bilateral tubal ligation (partner), hysterectomy (partner)).\n6. Participants should be able to read, understand, and to provide voluntary consent.\n\nExclusion Criteria:\n\n1. Women who are currently pregnant or lactating.\n2. The participant has any active infection requiring medications per PI's discretion.\n3. The participant has any clinical signs or symptoms of infection per PI's discretion.\n4. The participant has hyperthermia or hypothermia.\n5. The participant has any known recent (within the last 6 months) coagulation anomalies that are not being medically treated and are not stable per PI's discretion.\n6. The participant has any abnormal laboratory values at the screening visit which the Investigator determines to be clinically significant and make the patient unsuitable for participation.\n7. The Investigator determines the patient to be unsuitable for participation for other reasons, such as, but not limited to deep vein thrombosis (DVT), pulmonary embolus, cardiac arrhythmia, or those who have a prothrombotic condition, or who require persistent oxygen supplementation.\n8. The participant has a substantial and persistent response to dopaminergic medications.\n9. The participant has unexplained anosmia.\n10. The participant has fluctuating cognition, early dementia, or hallucinations.\n11. The participant has certain eye movement abnormalities.\n12. The participant has any MRI findings that suggest an alternative diagnosis.","EXPANDED_ACCESS","This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass pre-screening and a completed screening. The subjects will receive 12 intravenous infusions of HB-adMSCs and 6 intrathecal injections of HB-adMSCs over the course of 44 weeks (1 infusion each month and 1 injection every other month).",[30],[320,321,322],"msa","stem cells","MSCs","AVAILABLE","2026-04-14",{"date":326,"type":41},"2026-04-17",{"name":328,"class":99},"Hope Biosciences Research Foundation",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":16,"minAge":130,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":258},"100496729","pain-and-autonomic-symptoms-in-parkinsons-disease-and-atypical-parkinsonisms-100496729","NCT05748028","Pain and Autonomic Symptoms in Parkinson's Disease and Atypical Parkinsonisms","Pain and Autonomic Symptoms in Parkinson's Disease and Atypical Parkinsonisms: Identification of Predictive Patterns of Rehabilitation Outcome and Evaluation of the Impact on Quality of Life","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's Disease or Multiple System Atrophy according to current international criteria (Gilman S et al, 2008; Postuma RB et al. 2015).\n* Mini-Mental State Examination score at least 10\n\nExclusion Criteria:\n\n* vascular or pharmacological parkinsonism\n* diabetes mellitus\n* hepatic or renal dysmetabolism,\n* hypothyroidism or hyperthyroidism\n* assumption of potentially neurotoxic drugs",{"count":337,"type":21},280,"The goal of this observational study is to learn about the impact of the different types of pain and of the domains involved in the autonomic disorders of inpatients and outpatients diagnosed with Parkinson disease (PD) and multiple system atrophy (MSA) admitted to Istituti Clinici Scientifici Maugeri Centers.\n\nThe main aims are:\n\nEvaluate the prevalence of pain and characterize it in Parkinson's disease and atypical parkinsonisms (MSA) Evaluate the effect of rehabilitation on pain and autonomic symptoms Evaluate the prevalence of autonomic symptoms in Parkinson's disease and atypical parkinsonisms (MSA) Assess the impact of pain and autonomic symptoms on quality of life. Participants will perform neurological examination, rehabilitation program and clinical scales.\n\nResearchers will compare the two groups of patients (PD and MSA) and the effect of the rehabilitation on pain, autonomic symptoms and quality of life.",[139,30],[341,342,343],"pain","autonomic symptoms","rehabilitation",{"date":326,"type":41},{"date":346,"type":41},"2019-06-15",{"date":148,"type":21},{"name":349,"class":48},"Istituti Clinici Scientifici Maugeri SpA",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":316,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":323,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":361,"locationsCount":4},"100633803","post-trial-access-to-ath434-for-patients-with-multiple-system-atrophy-100633803","NCT07531433","Post-Trial Access to ATH434 for Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Completed Alterity protocol ATH434-201 or ATH434-202\n* Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician\n\nExclusion Criteria:\n\n* Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason\n* Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion","This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.",[30],"2026-04-09",{"date":360,"type":41},"2026-04-15",{"name":362,"class":99},"Alterity Therapeutics",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":387},"100632832","phase-2-efficacy-and-safety-of-butylphthalide-in-the-treatment-of-multiple-system-atrophy-100632832","NCT07518810","Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy","Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy（ENMSA）: A Multicenter, Randomised, Double-blinded, Placebo-controlled Trial","ENMSA","Inclusion Criteria:\n\n1. Meet a diagnosis for \"clinically established MSA\" according to the Movement Disorder Society (MDS) diagnostic criteria for multiple system atrophy revised in 2022, as assessed by a neurologist;\n2. Patients aged between 30 and 80 years, within 5 years since the initial diagnosis of MSA, and with a life expectancy greater than 3 years;\n3. Patients are not entirely dependent on a wheelchair or bedridden and are capable of cooperating with necessary assessments and examinations, including scale evaluations, magnetic resonance imaging (MRI), and PET-CT scans;\n4. Patients must have been on a stable medication regimen (for a duration of at least one month) prior to the trial, which may include drugs for anti-Parkinson, anti-autonomic dysfunction, anti-anxiety\u002Fdepression agents, and sleep aids\n\nExclusion Criteria:\n\n1. Patients with a diagnosis confirmed by PET-CT or revised during follow-up to other diseases, such as idiopathic Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, or secondary parkinsonian syndromes.\n2. Patients with a history of other major neurological disorders, including ischemic stroke, intracranial hemorrhage, epilepsy, encephalitis, or central nervous system demyelinating diseases;\n3. Patients with a history of psychiatric disorders that may involve psychotic symptoms, such as schizophrenia, major depressive disorder, or dissociative -conversion disorders.\n4. Patients with severe hepatic or renal impairment (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] levels \\>2 xULN; Estimated creatinine clearance \\\u003C30 mL\u002Fmin;\n5. Patients with a heamorrhage event within the past 3 months or a high bleeding risk;\n6. Patients with a history of significant craniocerebral trauma or surgery;\n7. Patients with severe cognitive impairment (Mini-Mental State Examination \\[MMSE\\] score \\\u003C24);\n8. Patients with a history of malignancy or autoimmune diseases;\n9. Patients with dysphagia due to severe medullary dysfunction or esophageal disorders, or those unable to comply with medication administration for other reasons;\n10. Patients who are pregnant, lactating, or planning a pregnancy within the next year.",{"count":372,"type":21},150,[87,374],"PHASE3","The present study aims to conduct a randomized controlled trial to evaluate the efficacy and safety of 3-n-Butylphthalide (NBP) in improving symptoms in patients with Multiple System Atrophy (MSA). The main questions it aims to answer are:\n\n1. To evaluate whether NBP soft capsules, compared with placebo, alleviates the major clinical symptoms in patients with MSA.\n2. Whether NBP application is safe to treat patients with MSA. In this trial, NBP will be compared with placebo (similar soft capsule without effective component of NBP) to demonstrate if NBP can alleviates MSA symptoms\n\nParticipants of ENMSA will:\n\n1. Take NBP or Placebo three times a day for 6 months\n2. Be served with clinical visit four times for follow-up and tests\n3. Keep a diary of drug application and symptom changes",[30],[222,378],"3-n-butylphthalide","2026-04-02",{"date":358,"type":41},{"date":382,"type":21},"2026-04-10",{"date":384,"type":21},"2027-10-10",{"name":386,"class":48},"Second Affiliated Hospital, School of Medicine, Zhejiang University",6,{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":160,"sex":16,"minAge":395,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":412,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":236},"100299199","the-swedish-biofinder-2-study-100299199","NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA\n\n* Age 66-100 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 26-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints.\n* MMSE score of 24 - 30 points.\n* Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V.\n* The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42\u002F40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints.\n* MMSE score of 12-26 points.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V).\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT E: Other dementias INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS.\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.","20 Years","100 Years",{"count":398,"type":21},2950,[24],"The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.\n\nThe original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: \"Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.",[402,403,139,404,405,406,407,408,64,409,30,410,411],"Dementia","Alzheimer Disease","Lewy Body Disease","Parkinson-Dementia Syndrome","Frontotemporal Degeneration","Semantic Dementia","Progressive Nonfluent Aphasia","Corticobasal Degeneration","Mild Cognitive Impairment","ALS (Amyotrophic Lateral Sclerosis)",[413],"Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test","2026-04-01",{"date":416,"type":41},"2026-04-06",{"date":418,"type":41},"2017-05-15",{"date":420,"type":21},"2036-12",{"name":422,"class":48},"Skane University Hospital",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":49},"100476871","cpap-for-the-treatment-of-supine-hypertension-100476871","NCT05489575","CPAP for the Treatment of Supine Hypertension","Hemodynamic Effects of Positive Airway Pressure to Treat Supine Hypertension and Improve Neurogenic Orthostatic Hypotension","Inclusion Criteria:\n\n* Male and female subjects, age 40-80 years, with autonomic failure including pure autonomic failure, multiple system atrophy and Parkinson disease.\n* Neurogenic orthostatic hypotension, defined as a ≥20-mmHg decrease in systolic blood pressure within 3 minutes of standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes.\n* Nocturnal supine hypertension (nighttime systolic blood pressure ≥140 mmHg) during the overnight screening for supine hypertension.\n* Patients who are willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients with history of recent facial trauma or surgery or intolerance to CPAP or to the CPAP mask.\n* Patients who cannot tolerate the medication withdrawal, defined as those who are unable to stand for at least one minute or those with sustained supine blood pressure ≥180\u002F110 mmHg after the medication withdrawal period.\n* Bedridden patients or those who are unable to stand due to motor impairment or severe orthostatic hypotension.\n* Smokers, patients who are pregnant, or have clinically unstable coronary artery disease, or major cardiovascular or neurological event in the past 6 months; heart failure; and other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical or laboratory testing.",{"count":431,"type":21},59,[24],"This study aims to learn about the effects of continuous positive airway pressure (CPAP) on people with autonomic failure and high blood pressure when lying down (supine hypertension) to determine if it can be used to treat their high blood pressure during the night. CPAP (a widely used treatment for sleep apnea) involves using a machine that blows air into a tube connected to a mask covering the nose, or nose and mouth, to apply a low air pressure in the airways.\n\nThe study includes 3-5 days spent in the Vanderbilt Clinical Research Center (CRC): at least one day of screening tests, followed by up to 3 study days. Subjects may be able to participate in daytime and\u002For overnight studies. The Daytime study consists of 2 study days: one with active CPAP and one with sham CPAP applied for up to 2 hours. The Overnight study consists of 3 study nights: one with active CPAP, one with sham CPAP, both applied for up to 9 hours and one night sleeping with the bed tilted head-up.",[28,29,30,139,435,137],"Supine Hypertension",[437,438,439],"CPAP","Hypertension","Orthostatic hypotension","2026-03-31",{"date":442,"type":41},"2026-04-07",{"date":444,"type":41},"2022-06-23",{"date":446,"type":21},"2027-08-31",{"name":47,"class":48},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":49},"100568602","phase-1-autologous-sural-nerve-grafting-to-the-substantia-nigra-in-patients-with-synuclienopathies-100568602","NCT06683365","Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies","A Phase I Study of the Feasibility and Safety of SuraL nervE Tissue Grafting to the Substantia nigrA in Patients With Synucleinopathies (LEAP)","LEAP","Inclusion Criteria:\n\n* Diagnosis of clinically established or clinically probable PD or MSA as defined by MDS criteria\n* Disease duration greater than 2 years\n* Age 40-75, inclusive\n* MDS-Unified Parkinson's Disease Rating Scale (UPDRS) Part III greater than or equal to 20 points but less than or equal to 35 points, off anti-parkinsonian medication for PD or MDS-Unified Multiple System Atrophy Rating Scale (UMSARS) less than or equal to 30 points off anti-parkinsonian medication\n* No MDS-UPDRS Part III score \\>3 on items 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.14 while off medication\n* Able and willing to undergo ioflupane\u002FSPECT\n* Able to tolerate the surgical procedure\n* Able to undergo all planned assessments\n* Available access to the sural nerve\n\nExclusion Criteria:\n\n* Previous PD surgery or intracranial surgery\n* Ongoing major medical or psychiatric disorder incl. depression and psychosis\n* Other concomitant treatment with neuroleptics\n* Typical, nonparkinsonian syndrome ioflupane\u002FSPECT signal\n* Unable to undergo an MRI\n* An obstructed trajectory path to the substantia nigra\n* Significant microvascular disease\n* Use of anticoagulants other than aspirin\n* Female who is pregnant, lactating, or of child-bearing potential unwilling to use an adequate birth control method during the period of the study\n* Consent capacity will be assessed and determined during and throughout a participant's neuropsychological exam. A participant who experiences a decline in consent capacity prior to surgery, will be removed from the study by the PI. A decline in consent capacity after surgery will not result in the removal of the participant in the study.",{"count":457,"type":21},7,[271],"This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed initially for one year after surgery.",[30,461],"Parkinsons Disease",[463,464,30,461],"Synucleinopathies","Cell and Tissue Based Therapy","2026-03-26",{"date":414,"type":41},{"date":468,"type":41},"2025-02-25",{"date":470,"type":21},"2030-12-02",{"name":472,"class":48},"Craig van Horne, MD, PhD",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":16,"minAge":57,"maxAge":109,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":225,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":49},"100629567","early-phase-1-expansion-study-of-alt001-in-patients-with-multiple-system-atrophy-100629567","NCT07476352","Expansion Study of ALT001 in Patients With Multiple System Atrophy","ALT001 in MSA","Inclusion Criteria:\n\n* 1\\. Age between 30 and 75 years inclusive, either sex;\n* 2\\. Clinically established or clinically probable MSA (including both MSA-C and MSA-P subtypes);\n* 3\\. Ability to walk independently or with the aid of a walking device for at least 10 meters;\n* 4\\. Provision of written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Evidence of other central nervous system pathologies on brain MRI at screening suggesting a diagnosis of neurodegenerative diseases other than MSA;\n* 2\\. Other significant pathological findings on brain MRI at screening, including but not limited to: cerebral hemorrhage, acute cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter \\\u003C1 cm do not require exclusion);\n* 3\\. Presence of immune-mediated diseases that are inadequately controlled or require treatment with biologic agents;\n* 4\\. Known history of allergies to biologic agents, such as proteins or cell-based products;\n* 5\\. Receipt of any vaccination within the past 1 month;\n* 6\\. Patients with a prior definitive diagnosis of malignancy or those currently receiving anti-tumor drug therapy;\n* 7\\. Patients with a prior definitive diagnosis of epilepsy or those currently taking anti-epileptic drugs;\n* 8\\. Concurrent severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency (severe hepatic insufficiency defined as ALT ≥1.5 times the upper limit of normal or AST ≥1.5 times the upper limit of normal; severe renal insufficiency defined as serum creatinine \\[CRE\\] ≥1.5 times the upper limit of normal or estimated glomerular filtration rate \\[eGFR\\] \\\u003C40 mL\u002Fmin\u002F1.73 m²; severe cardiac insufficiency defined as NYHA class 3-4), or any significant abnormalities on physical examination, vital signs, laboratory tests, or electrocardiogram that, in the investigator's opinion, require further examination or treatment, or may interfere with the study procedures or safety;\n* 9\\. Patients with a history of alcohol or substance abuse, or alcohol or substance dependence within the past 2 years;\n* 10\\. Patients diagnosed with psychiatric disorders according to DSM-V criteria, or those with obvious suicidal intent;\n* 11\\. Patients who are pregnant, lactating, or have the potential to become pregnant, or those planning a pregnancy;\n* 12\\. Inability to comply with follow-up assessments due to other reasons;\n* 13\\. Patients deemed by the investigator to be unsuitable for participation in this study.",{"count":123,"type":21},[482],"EARLY_PHASE1","This is an open-label, single-center, prospective, single-arm clinical study. The primary objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of ALT001 in the treatment of patients with multiple system atrophy (MSA) in a real-world setting.",[30],[168],"2026-03-25",{"date":488,"type":41},"2026-03-30",{"date":490,"type":21},"2026-05-06",{"date":492,"type":21},"2027-10-30",{"name":494,"class":48},"yilong Wang",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":160,"sex":16,"minAge":130,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":22,"phases":502,"briefSummary":503,"conditions":504,"keywords":505,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":49},"100381425","phase-1-18ff-dopa-imaging-in-patients-with-autonomic-failure-100381425","NCT04246437","[18F]F-DOPA Imaging in Patients With Autonomic Failure","Inclusion Criteria:\n\n1. Patients with a diagnosis if pure autonomic failure\n2. Patients with autonomic failure and possible PD, MSA, or DLB\n3. Healthy adults aged 18 and above\n4. Clinical exam confirming clinical designation\n\nExclusion Criteria:\n\n* Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.), because such devices may be displaced or malfunction.\n* Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced.\n* Subjects who have cerebral aneurysm clips.\n* Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes).\n* Subjects who are pregnant, because the effects of high field MRI on fetuses are not yet known.\n* Minors (younger than 18 years)\n\nAlso excluded are subjects incapable of giving informed written consent:\n\n* Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher.\n* Subjects who have limited mental ability to give informed consent, mentally retarded, altered mental status, mental disability, confusion, or psychiatric disorders.\n* Prisoners",{"count":269,"type":21},[271],"Alpha-synucleinopathies refer to age-related neurodegenerative and dementing disorders, characterized by the accumulation of alpha-synuclein in neurons and\u002For glia. The anatomical location of alpha-synuclein inclusions (Lewy Bodies) and the pattern of progressive neuronal death (e.g. caudal to rostral brainstem) give rise to distinct neurological phenotypes, including Parkinson's disease (PD), Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB). Common to these disorders are the involvement of the central and peripheral autonomic nervous system, where Pure Autonomic Failure (PAF) is thought (a) to be restricted to the peripheral autonomic system, and (b) a clinical risk factor for the development of a central synucleinopathy, and (c) an ideal model to assess biomarkers that predict phenoconversion to PD, MSA, or DLB. Such biomarkers would aid in clinical trial inclusion criteria to ensure assessments of disease- modifying strategies to, delay, or halt, the neurodegenerative process. One of these biomarkers may be related to the neurotransmitter dopamine (DA) and related changes in the substantia nigra (SN) and brainstem. \\[18F\\]F-DOPA is a radiolabeled substrate for aromatic amino acid decarboxylase (AAADC), an enzyme involved in the production of dopamine. Use of this radiolabeled substrate in positron emission tomography (PET) may provide insight to changes in monoamine production and how they relate to specific phenoconversions in PAF patients. Overall, this study aims to identify changes in dopamine production in key regions including the SN, locus coeruleus, and brainstem to distinguish between patients with PD, MSA, and DLB, which may provide vital information to predict conversion from peripheral to central nervous system disease.",[28,29,139,30,140],[506,507],"FDOPA","PET","2026-03-12",{"date":510,"type":41},"2026-03-16",{"date":512,"type":41},"2020-02-04",{"date":514,"type":21},"2027-02-01",{"name":516,"class":48},"Daniel Claassen",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":523,"targetDuration":525,"studyType":133,"phases":4,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":49},"100620118","shanghai-clinical-cohort---parkinsons-disease-reserve-100620118","NCT07353463","Shanghai Clinical Cohort - Parkinson's Disease (Reserve)","* Inclusion Criteria for Clinical PD Group:\n\n  1. Patients with a clinical diagnosis of Parkinson's disease (PD) according to the \\_Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)\\_.\n  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET\u002FSPECT) and disease-specific clinical assessments.\n  3. Provision of written informed consent\n* Inclusion Criteria for Clinical MSA Group:\n\n  1. Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022).\n  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET\u002FSPECT) and disease-specific clinical assessments.\n  3. Provision of written informed consent.\n* Exclusion Criteria for All Participants:\n\n  1. Patients with an unclear or uncertain diagnosis.\n  2. History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery.\n  3. Evidence of intracranial organic lesions on CT\u002FMRI.\n  4. Severe anxiety, depression, or schizophrenia.\n  5. Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system.\n  6. Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments.\n  7. Anticipated poor compliance.",{"count":524,"type":21},700,"1 Year","The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development.\n\nThe main questions it aims to answer are:\n\n* Can multimodal data (clinical, imaging, electrophysiology, biospecimens, and genetics) help identify early biomarkers for PD and MSA?\n* Can precise subtyping and long-term monitoring predict disease progression and therapeutic response? Researchers will compare 600 PD patients and 100 MSA patients to evaluate differences in clinical features, biomarkers, imaging, and prognosis.\n\nParticipants will:\n\n* Provide informed consent and complete baseline demographic and medical history collection.\n* Undergo standardized clinical evaluations, including motor and non-motor symptom scales, cognitive and quality-of-life assessments.\n* Provide biological samples (blood, saliva, optional CSF).\n* Receive brain imaging (MRI, optional PET\u002FSPECT) and electrophysiological recordings (EEG, fNIRS).\n* Participate in longitudinal follow-up visits every 6 months for repeat assessments.\n\nThis study will create a sustainable, multicenter, and sharable cohort platform to support early identification, personalized intervention, and therapeutic development for neurodegenerative diseases",[528,30],"Parkinson's Disease (PD)",[530,531,532,533],"observational cohort study","multimodal data","subtyping","long-term monitoring","2026-03-03",{"date":536,"type":41},"2026-03-05",{"date":538,"type":41},"2025-04-01",{"date":255,"type":21},{"name":541,"class":48},"Ruijin Hospital",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":16,"minAge":549,"maxAge":18,"enrollmentInfo":550,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":552,"conditions":553,"keywords":554,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":49},"100448558","synaptic-loss-in-multiple-system-atrophy-100448558","NCT05121012","Synaptic Loss in Multiple System Atrophy","Molecular Imaging of Synaptic Loss in Multiple System Atrophy (MSA)","Inclusion Criteria\n\nMSA group:\n\nMale or female, aged 45-80 at the time of informed consent. Meet criteria for diagnosis of probable or possible MSA (Gilman et al., 2008) (Appendix 1).\n\nA female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day), is not lactating and is willing to use one of the contraception methods listed below:\n\n* Combined (estrogen and progesterone containing) hormonal contraception associated with initiation of ovulation( oral, intravaginal, or transdermal);\n* Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);\n* Intrauterine device;\n* Intrauterine hormone releasing system;\n* Bilateral tubal occlusion;\n* Vasectomized partner;\n* Sexual abstinence.\n\nMale subject with a female partner of child-bearing potential must use one of the following contraceptive methods for 90 days after each dose of radiotracer:\n\n* Condom plus partner use of a highly effective contraceptive (see point above) OR\n* Abstinence Subjects must understand the nature of the study and be able to provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-related procedures. They must be able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.\n\nMust have anticipated survival of ≥3 years (in the opinion of the Investigator).\n\nMedical treatment of MSA and co-morbid medical conditions must be stable for at least 30 days prior to screening and between screening and baseline PET scan. Intermittently administered treatment may be considered stable if the dose and dosing frequency have been unchanged for the greater of 30 days or three dosing inbiomartervals (e.g. a treatment given once a month must be at a stable dose and dosing frequency for 3 months).\n\nFor inclusion in optional CSF sampling, written informed consent must be provided, either by separate signed and dated written informed consent or by specific written acknowledgement on the main study informed consent form, according to local procedure. Failure to participate in optional CSF sampling will have no influence on the subject's ability to participate in the main study.\n\nIn the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have high probability of completing the study.\n\nPSP Group:\n\nMale or female, aged 45-80 at the time of informed consent. Meet criteria for diagnosis of suggestive, probable or possible PSP - with preference for PSP-RS, PSP-OM, PSP-PI, PSP with gait freezing, and PSP-SL and PSP-P subtypes (Höglinger et al., 2017 (Appendix 2).\n\nA female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day), is not lactating and is willing to use one of the contraception methods listed below:\n\n* Combined (estrogen and progesterone containing) hormonal contraception associated with initiation of ovulation( oral, intravaginal, or transdermal);\n* Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);\n* Intrauterine device;\n* Intrauterine hormone releasing system;\n* Bilateral tubal occlusion;\n* Vasectomized partner; Sexual abstinence.\n\nMale subject with a female partner of child-bearing potential must use one of the following contraceptive methods for 90 days after each dose of radiotracer:\n\n• Condom plus partner use of a highly effective contraceptive (see point above) OR Abstinence Subjects must understand the nature of the study and be able to provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-related procedures. They must be able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.\n\nExclusion criteria:\n\nMSA group:\n\nHistory of other neurological disorders or intracranial co-morbidities, such as stroke, haemorrhage, space-occupying lesions.\n\nPresence of supranuclear gaze palsy. Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgement of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results.\n\nSevere-to-complete dependence on caregivers (score \\>3 on UMSARS Part IV, Global Disability), severe impairment of swallowing (score ≥3 on UMSARS Part I, Question 2), or frequent falls (score ≥3 on UMSARS Part I, Question 8) at Screening.\n\nPresence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g. Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body. If the principal investigator considers the presence of any of the above not to be a contraindication to MRI in a given subject, the investigator may obtain approval from the MR operators based on a discussion of the case.Negative modified Allen test in both hands.\n\nHistory of claustrophobia or back pain that makes prolonged laying on the MRI or PET scanner intolerable.\n\nPregnancy, lactation, or, if female of childbearing potential, positive urine β-hCG at screening or prior to PET scan.\n\nUse of drugs acting on SV2A such as antiepileptics (e.g. levetiracetam or brivaracetam).\n\nHistory of brain surgery for parkinsonism or stem cell treatment. Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology.\n\nCurrent or recent history of alcohol or drug abuse \u002F dependence (except nicotine dependence).\n\nHistory of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin.\n\nHemoglobin A1c (HbA1c) ≥ 6.5% at screening. Uncontrolled\u002Fpoorly controlled diabetes mellitus.\n\nFor subjects participating in optional CSF sampling:\n\n* Any spinal malformation or other aspects (e.g. tattoos) \u002F clinical findings (e.g. papilledema) that may complicate or contraindicate lumbar puncture, as judged by the investigator.\n* Neoplasm or other space-occupying intracranial lesion on MRI. Any clinically important abnormality, as determined by the investigator, on physical examination or vital signs, ECG, or clinical laboratory test results other than abnormality due to a stable, well-controlled medical condition; or any abnormality that could be detrimental to the subject or could compromise the study.\n\nPSP group:\n\nHistory of other neurological disorders or intracranial co-morbidities, such as stroke, haemorrhage, space-occupying lesions.\n\nInclusion in any clinical trial with investigational drugs targeting tau. Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgement of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results.\n\nPresence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g. Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body. If the principal investigator considers the presence of any of the above not to be a contraindication to MRI in a given subject, the investigator may obtain approval from the MR operators based on a discussion of the case.\n\nAbnormal modified Allen test in both hands. History of claustrophobia or back pain that makes prolonged laying on the MRI or PET scanner intolerable.\n\nPregnancy, lactation, or, if female of childbearing potential, positive urine β-hCG at screening or prior to PET scan.\n\nHistory of brain surgery for parkinsonism or stem cell treatment. Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology.\n\nCurrent or recent history of alcohol or drug abuse \u002F dependence (except nicotine dependence).\n\nHistory of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin.\n\nFor subjects participating in optional CSF sampling:\n\n• Any spinal malformation or other aspects (e.g. tattoos) \u002F clinical findings (e.g. papilledema) that may complicate or contraindicate lumbar puncture, as judged by the investigator.\n\nNeoplasm or other space-occupying intracranial lesion on MRI. Any clinically important abnormality, as determined by the investigator, on physical examination or vital signs, ECG, or clinical laboratory test results other than abnormality due to a stable, well-controlled medical condition; or any abnormality that could be detrimental to the subject or could compromise the study.","45 Years",{"count":551,"type":21},36,"In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology related to abnormal accumulation of a protein named tau, in Progressive Supranuclear Palsy (PSP).",[30,216],[555,556,30,557,64],"Neurodegeneration","Positron Emission Tomography","Biomarkers","2026-02-06",{"date":560,"type":41},"2026-02-10",{"date":562,"type":41},"2021-09-01",{"date":564,"type":21},"2027-03-31",{"name":566,"class":48},"University of Exeter",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":160,"sex":16,"minAge":573,"maxAge":109,"enrollmentInfo":574,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":49},"100623113","study-on-artificial-intelligence-based-facial-and-speech-related-patterns-in-parkinsons-disease-and-their-digital-biomarkers-100623113","NCT07392411","Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers","Inclusion Criteria:\n\n1. Inclusion Criteria for Parkinson's Disease (PD) Group: (1) Diagnostic Criteria: Meet the diagnostic criteria for Parkinson's disease established by the Movement Disorder Society (MDS) in 2015. (2) Age Range: 18-75 years old. (3) Disease Severity: Early-stage PD: Hoehn-Yahr score ≤ 2.5 points. Mid-to-late-stage PD: Hoehn-Yahr score 2.5-5 points. (4) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (5) Informed Consent: Signed informed consent form.\n2. Inclusion Criteria for Parkinson's Plus Syndromes (MSA-P, PSP) Group: (1) Age Range: 18-75 years old. (2) Diagnostic Criteria: MSA patients must meet the diagnostic criteria established by the \\[Chinese Expert Consensus on the Diagnosis of Multiple System Atrophy, 2017\\]. PSP patients must meet the diagnostic criteria established by the \\[Chinese Clinical Diagnostic Criteria for Progressive Supranuclear Palsy, 2016 Edition\\]. (3) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (4) Informed Consent: Signed informed consent form.\n\nExclusion Criteria:\n\n1. History of cerebrovascular disease, head trauma, hydrocephalus, brain tumors, or intracranial surgery.\n2. Presence of metal implants, cardiac pacemakers, or other metallic foreign bodies (applies to PD patients).\n3. Severe dyskinesia in PD patients that would compromise cooperation with video\u002Faudio recording.\n4. Mini-Mental State Examination (MMSE) score ≤ 24 points.","15 Years",{"count":575,"type":21},720,"This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.",[63,578,30,579],"Progressive Supranuclear Palsy(PSP)","Healthy Control","2026-01-30",{"date":558,"type":41},{"date":583,"type":41},"2023-07-25",{"date":255,"type":21},{"name":586,"class":48},"Beijing Tiantan Hospital",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":160,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":49},"100352687","facilitating-diagnostics-and-prognostics-of-parkinsonian-syndromes-using-neuroimaging-100352687","NCT03872102","Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging","Quantitative Diagnostics of Parkinsonian Syndromes Using Multi-modal Neuroimaging and Deep Learning","Inclusion Criteria:\n\nFor Aim 1:\n\n* Diagnosis of Parkinson disease\n* Existence of sufficient clinical data from previous UTS Southwestern longitudinal study to determine progression rate (categorized as fast or slow)\n* Availability of suitable matched participant in the alternate progression group (fast or slow)\n* Willingness to participate in the imaging studies required for this study and to provide written informed consent\n\nFor Aim 2:\n\nPD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for PD.\n\n* Duration of PD (since diagnosis) is \\\u003C 5 years\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move)\n\nMSA subjects will be recruited in accordance with the Second Consensus Statement on Diagnosis of Multiple System Atrophy.\n\n* Duration of MSA (since diagnosis) is \\\u003C 5 years\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)\n\nPSP subjects will be recruited in accordance with the MDS Criteria for Diagnosis of Progressive Supranuclear Palsy and must meet the designation of \"probable PSP\" for inclusion.\n\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)\n\nControl subjects will be recruited who meet the following criteria:\n\n* Roughly age and sex matched with the subjects in the PD cohort\n* No history or examination findings suggestive of any neurodegenerative disease\n* Normal gait, balance, and eye movements for age\n* No clinical evidence for symptomatic orthostatic hypotension\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)\n\nExclusion Criteria:\n\nFor Aims 1 and 2:\n\n* Any contraindications to undergoing the multimodal imaging program\n* All females of child-bearing potential, between the ages of 18-55, will be excluded from the study, unless they are confirmed to be not pregnant with a pregnancy test prior to scanning\n* This study will require constant clear communication throughout the duration of the study; therefore, non-English speakers will be excluded\n* Right-handed finger amputees\n* Cast on right hand or fingers at the time of enrollment\n* Has clinically significant liver, kidney, lung, metabolic or hormone disturbances which pose safety risk\n* Has a current clinically significant heart disease that poses a safety risk\n* Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk\n* Has a history of relevant severe drug allergy or hypersensitivity\n* Have a history of drug, alcohol, or substance dependence or abuse within the last year, or prior prolonged history of dependence or abuse\n* Currently undergoing chemotherapy or radiation for cancer\n* Recreational drug use in past six months\n* Central nervous systems disease or brain injury that would preclude participation in this study\n* Psychiatric or neurological disorder that would preclude participation in this study\n* Inability to keep or maintain research appointments\n\nFor Aim 1:\n\n* Severe disease progression such that participation in the imaging tests would be impossible or difficult\n* Non-availability of a suitable matched participant in the alternate progression group (fast or slow)\n\nFor Aim 2:\n\nPD subjects\n\n1. Unequivocal cerebellar abnormalities\n2. Downward vertical gaze limitation or slowing of downward saccades\n3. Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia\n4. Parkinsonian features restricted to the lower limbs for \\> 3 years\n5. Treatment with dopamine blockers or depleters in a time course consistent with drug induced parkinsonism\n6. Absence of an observable response to high dose levodopa despite moderate disease severity\n7. Expert considers a diagnosis of alternative syndrome more likely than PD\n8. Rapid progression of gait impairment requiring wheelchair within 5 years of onset\n9. Complete absence of progression of motor symptoms over 5 years unless due to treatment\n10. Early bulbar dysfunction within the first 5 years since diagnosis\n11. Inspiratory respiratory dysfunction (stridor or frequent sighs)\n12. Severe autonomic failure in the first 5 years\n13. Recurrent falls (\\>1 per year) because of impaired balance in the first 3 years\n14. Disproportionate dystonic anterocollis or hand contractures of hands or feet within 10 years\n15. Absence of any of the common non-motor features of PD despite 5 years of disease\n16. Otherwise unexplained pyramidal tract signs (weakness, hyperreflexia, or extensor toe signs)\n17. Bilateral symmetric parkinsonism\n\nMSA subjects\n\n1. Clinically significant neuropathy\n2. Hallucinations not induced by drugs\n3. Onset after age 75 years\n4. Family history of ataxia or parkinsonism\n5. White matter lesions suggesting multiple sclerosis\n\nPSP subjects\n\n1. Predominant, otherwise unexplained impairment of episodic memory, suggestive of AD (Alzheimer's disease)\n2. Predominant, otherwise unexplained autonomic failure, e.g., orthostatic hypotension (orthostatic reduction in blood pressure after 3 minutes standing \\> 30 mm Hg systolic or \\> 15 mm Hg diastolic), suggestive of multiple system atrophy or Lewy body disease\n3. Predominant, otherwise unexplained visual hallucinations or fluctuations in alertness, suggestive of dementia with Lewy bodies\n4. Predominant, otherwise unexplained multisegmental upper and lower motor neuron signs, suggestive of motor neuron disease (pure upper motor neuron signs are not an exclusion criterion)\n5. Sudden onset or step-wise or rapid progression of symptoms, in conjunction with corresponding imaging or laboratory findings, suggestive of vascular etiology, autoimmune encephalitis, metabolic encephalopathies, or prion disease\n6. History of encephalitis\n7. Prominent appendicular ataxia\n8. Identifiable cause of postural instability, e.g., primary sensory deficit, vestibular dysfunction, severe spasticity, or lower motor neuron syndrome\n\nControl subjects\n\na. In the investigator's opinion, an unsuitable candidate to serve as a control",{"count":595,"type":21},90,"The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.",[139,30,64],"2026-01-25",{"date":600,"type":41},"2026-01-27",{"date":602,"type":41},"2019-03-28",{"date":255,"type":21},{"name":605,"class":48},"University of Texas Southwestern Medical Center",{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":16,"minAge":130,"maxAge":18,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":615,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":627,"locationsCount":49},"100289072","overnight-trials-with-heat-stress-in-autonomic-failure-patients-with-supine-hypertension-100289072","NCT03042988","Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension","Overnight Trials to Compare the Effects of Controlled Heat Stress Versus Sham Control on Nocturnal Supine Hypertension in Autonomic Failure Patients","Inclusion Criteria:\n\n* Male and female patients, between 18-80 yrs., with primary autonomic failure (Parkinson Disease, Multiple System Atrophy, and Pure Autonomic Failure) and supine hypertension. Supine hypertension will be defined as SBP≥150 mmHg.\n* Patients able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Significant cardiac, renal or hepatic illness, or with contraindications to administration of pressor agents or with other factors, which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing.",{"count":614,"type":21},20,[24],"Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing), and at least half of them also have high blood pressure while lying down (supine hypertension). Exposure to heat, such as in hot environments, often worsens their orthostatic hypotension. The causes of this are not fully understood. The purpose of this study is to evaluate whether applying local heat over the abdomen of patients with autonomic failure and supine hypertension during the night would decrease their nocturnal high blood pressure while lying down. This will help us better understand the mechanisms underlying this phenomenon, and may be of use in the treatment of supine hypertension.",[438,29,30,28],[619,34,620,33],"supine hypertension","heat stress","2026-01-14",{"date":623,"type":41},"2026-01-16",{"date":625,"type":41},"2017-01-30",{"date":148,"type":21},{"name":47,"class":48}]